• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, June 17, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Business

Eylea biosimilar embarks on Phase 3 trial

by Myles Hume
August 20, 2020
in Business, Company updates & acquisitions, International, Local, Macular disease, News, Therapies
Reading Time: 2 mins read
A A
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

Share on FacebookShare on Twitter

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept).

Korean-based Samsung Bioepis has announced the Phase 3 clinical trial of SB15 will take place in eight countries, including South Korea. It is is a randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration.

According to industry sources, Korea’s health authorities gave Samsung Bioepis the go-ahead for a trial of SB15 following FDA approval for the trial in the US.

Ultimately, the company intends to commercialise its own cheaper versions of the macular disease treatments in major global markets, including the US, Canada, Europe, Japan and Australia.

It follows the company’s recent completion of a Phase 3 study of SB11, a biosimilar of Lucentis (ranibizumab), another commonly prescribed age-related macular degeneration (AMD) therapy.

Compared with Lucentis, which was used as the reference drug, SB11 demonstrated equivalent efficacy in terms of change in best corrected visual activity at week eight and central subfield thickness at week four.

Samsung Bioepis is now preparing to file a regulatory application seeking marketing approval for SB11.

It is aiming to capitalise on the expiration of patents for Lucentis and Eylea – both listed on the Australian Pharmaceutical Benefits Scheme – in the coming years and offer a cheaper alternative for health systems and patients in the US, Canada, Europe, Japan, and Australia.

If successfully commercialised, SB11 and SB15 would be the first biosimilar versions of Lucentis (ranibizumab) and Eylea, arguably two of the most commonly prescribed AMD drugs on the market.

More reading

Drug developer hits major milestone with Lucentis biosimilar

Biogen unveils plan to commercialise Eylea and Lucentis generics

Tags: afliberceptanti-VEGFAustraliabiosimilarEyleaLucentismarketsranibizumabSamsung BioepisSamsung biopsesSB11SB15

Related Posts

The brand is renowned for “signature artisanal craftsmanship and precise engineering”. Image: Safilo.

Safilo launches Stuart Weitzman eyewear in Australia

by Staff Writer
June 17, 2025

Stuart Weitzman has expanded its global luxury brand footprint with a first eyewear collection available to Australian independent optical practices...

Studies show only about 17% of people are currently wearing lenses truly matching their visual sensitivity. Image: Rodenstock.

Understanding the concept of ‘visual sensitivity’

by Staff Writer
June 17, 2025

Even when a lens is designed identically for two different people, they can have a polarising visual experience. ALEX RIGBY...

The Eyerising device is reported to be the only red-light device with international regulatory approval outside of China. Image: Eyerising International.

Inclusion of red-light therapy in WSPOS 2025 Myopia Consensus Statement

by Myles Hume
June 16, 2025

Repeated low-level red-light (RLRL) therapy has been included in the 2025 Myopia Consensus Statement released by the World Society of...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited